Physician profile
Mark E Rose
NPI 1851382550
$21,193.61
in general payments reported to CMS, 2019-2025
49 companies · $4,084 in 2025
The $4,084 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,763 · 2020: $583 · 2021: $2,319 · 2022: $3,491 · 2023: $3,430 · 2024: $3,523 · 2025: $4,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $147 · Consulting Fee: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,764.24 |
| Education | $146.58 |
| Consulting Fee | $126.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $3,504.01 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $2,601.69 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $1,851.31 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,375.03 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Csl Behring | $1,254.83 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $1,019.65 | 2019-2025 | |
| Pfizer INC. | $936.98 | 2019-2025 | |
| Genentech USA, INC. | $818.96 | 2019-2025 | Xolair |
| Leo Pharma INC. | $810.26 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $766.79 | 2019-2025 | |
| Amgen INC. | $632.62 | 2021-2025 | Tezspire |
| Optinose US, INC. | $567.64 | 2019-2025 | |
| Abbvie INC. | $555.59 | 2021-2025 | Rinvoq |
| Pharming Healthcare, INC. | $386.94 | 2019-2025 | Ruconest |
| Mylan Specialty L.P. | $352.75 | 2019-2024 | Yupelri |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $333.84 | 2019-2025 | Xembify |
| Kaleo, INC. | $294.61 | 2019-2024 | Auvi-Q |
| Octapharma USA, INC. | $293.53 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $284.78 | 2021-2025 | Orladeyo |
| Shire North American Group INC | $261.75 | 2019 | |
| Siemens Medical Solutions USA, INC. | $236.62 | 2025 | Somatom Go.Top, Magnetom Vida, Biograph Trinion Ep Ct64 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.56 | 2019-2022 | |
| Galderma Laboratories, L.P. | $220.93 | 2025 | Nemluvio |
| Incyte Corporation | $185.63 | 2022-2025 | Opzelura |
| Ars Pharmaceuticals Operations, INC. | $152.74 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $142.86 | 2022-2025 | |
| Gc Biopharma USA, INC. | $127.24 | 2025 | Alyglo |
| Blueprint Medicines Corporation | $126.50 | 2022-2025 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $126.29 | 2019-2022 | |
| Bio Products Laboratory USA, INC. | $124.69 | 2022-2023 | Coagadex, Gammaplex |
| Baxter Healthcare | $118.40 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Kedrion Biopharma, INC. | $89.58 | 2023-2025 | Rhogam Ultra-Filtered Plus, Albuked, Kedrab |
| Viatris Specialty LLC | $72.08 | 2025 | Yupelri |
| Philips North America LLC | $51.84 | 2019 | |
| Ionis Pharmaceuticals, INC. | $33.80 | 2025 | Dawnzera |
| Organon LLC | $31.67 | 2025 | Vtama |
| Advanced Respiratory, INC | $24.34 | 2019-2020 | |
| Lilly USA, LLC | $23.19 | 2025 | Ebglyss |
| Merck Sharp & Dohme LLC | $22.68 | 2023 | |
| Sunovion Pharmaceuticals INC. | $22.10 | 2020 | |
| Aytu Biopharma, INC. | $19.19 | 2019 | |
| Hikma Pharmaceuticals USA | $18.07 | 2023 | Ryaltris |
| Dermavant Sciences, INC. | $17.61 | 2024 | Vtama |
| Phadia US INC. | $17.16 | 2021 | |
| Covis Pharma Gmbh | $15.86 | 2022 | |
| Horizon Therapeutics Plc | $15.18 | 2019 | |
| Eyevance Pharmaceuticals LLC | $13.39 | 2021 | |
| Aimmune Therapeutics, INC. | $12.93 | 2021 | |
| Cycle Pharmaceuticals INC | $1.92 | 2024 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.